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ttp://dx.doi.org/10.1016/j.ajpath.2014.04.001We tested the hypothesis that IL-19, a putative member of the type 2 helper T-cell family of anti-
inﬂammatory interleukins, can attenuate intimal hyperplasia and modulate the vascular smooth muscle
cell (VSMC) response to injury. Ligated carotid artery of IL-19 knockout (KO) mice demonstrated a
signiﬁcantly higher neointima/intima ratio compared with wild-type (WT) mice (P Z 0.04). More
important, the increased neointima/intima ratio in the KO could be reversed by injection of 10 ng/g per
day recombinant IL-19 into the KO mouse (PZ 0.04). VSMCs explanted from IL-19 KO mice proliferated
signiﬁcantly more rapidly than WT. This could be inhibited by addition of IL-19 to KO VSMCs (PZ 0.04
and P < 0.01). IL-19 KO VSMCs migrated more rapidly compared with WT (P < 0.01). Interestingly,
there was no type 1 helper T-cell polarization in the KO mouse, but there was signiﬁcantly greater
leukocyte inﬁltrate in the ligated artery in these mice compared with WT. IL-19 KO VSMCs expressed
signiﬁcantly greater levels of inﬂammatory mRNA, including IL-1b, tumor necrosis factor a, and
monocyte chemoattractant protein-1 in response to tumor necrosis factor a stimulation (P < 0.01 for
all). KO VSMCs expressed greater adhesion molecule expression and adherence to monocytes. Together,
these data indicate that IL-19 is a previously unrecognized counterregulatory factor for VSMCs, and its
expression is an important protective mechanism in regulation of vascular restenosis. (Am J Pathol
2014, 184: 2134e2143; http://dx.doi.org/10.1016/j.ajpath.2014.04.001)Supported by the National Heart, Lung, and Blood Institute/NIH grants
HL090885 and HL115575 (M.V.A.), American Heart Association grant
13GRNT1685003 (M.V.A.), predoctoral fellowship 12PRE12040331
(S.E.), and postdoctoral fellowship 11POST7530001 (K.G.).
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Disclosures: None declared.Despite aggressive dietary modiﬁcation, lipid-lowering
medications, and other medical therapy, vascular disease
continues to account for 50% of all mortality in the United
States. It is a signiﬁcant systemic problem contributing to
mortality of multiple diseases, including myocardial
infarction, stroke, renal failure, and peripheral vascular
disease, and will worsen with an increasing growing number
of patients with comorbidities, such as obesity, metabolic
syndrome, and type 2 diabetes mellitus (conditions linked
with atherosclerotic vascular disease). Intimal hyperplasia
subsequent to mechanical injury remains a clinically sig-
niﬁcant obstacle limiting the success of vascular interven-
tion.1,2 Even though intracoronary stents are more effective
than percutaneous transluminal coronary angioplasty alone
in decreasing restenosis, in up to 35% of cases, in-stent
restenosis occurs between 6 and 9 months.3e5 Further-
more, the incidence of clinical restenosis in selected patientstigative Pathology.
.populations, such as diabetics and those with complex le-
sions, can exceed 50%, signiﬁcantly limiting the success of
this modality.
As part of the response to injury, vascular smooth muscle
cells (VSMCs) migrate from the media into the lumen of the
vessel, where they proliferate and synthesize cytokines, which
they respond to in an autocrine fashion, sustaining the pro-
gression of intimal hyperplasia.6,7 VSMC migration, prolif-
eration, and matrix deposition are responsible for most of the
obliterative arterial intimal thickening present inmechanically
IL-19 Reduces Neointimal Hyperplasiainduced intimal hyperplasia and cardiac allograft vasculopathy,
and may be the most critical cellular events in neointima
development.6e8 The deleterious effects of proinﬂammatory
cytokines on VSMC pathophysiological characteristics and
development of many vascular diseases, ranging from athero-
sclerosis to transplant vasculopathy, have been well docu-
mented.Agap inour knowledge remains concerning the role of
anti-inﬂammatory cytokines in vascular biology, particularly
with respect to direct effects of these cytokines on VSMC
pathophysiological characteristics. Most of the emphasis on
secretion of inﬂammatory mediators has understandably been
placed on leukocytes. The role of nonimmune cells in this
process is poorly understood, but nevertheless intriguing,
especially considering VSMC phenotypic plasticity. Identiﬁ-
cation of anti-inﬂammatory factors, which also inhibit the
VSMC response to injury, is of obvious clinical importance.
IL-19 was ﬁrst described in 2001.9 The ﬁrst known IL-
10erelated cytokines were incorporated into the IL-10 family
in 2001 without any knowledge of their biological func-
tions,10 and IL-19 is now considered to be in a subfamily that
includes IL-19, IL-20, and IL-24. IL-19 is functionally
distinct from these subfamily members and IL-10.11,12 We
have previously described several studies that point to an
anti-inﬂammatory role of IL-19 outside the immune system,
with direct suppressive effects on VSMCs in particular.13e15
We have shown that adenoviral delivery of IL-19 reduces
intimal hyperplasia in the rat balloon angioplasty model.
Although exogenously delivered IL-19 is protective in
vascular injuries, no studies have taken advantage of genet-
ically modiﬁed mice to characterize a precise cause-and-
effect role of this interleukin in the VSMC response to
injury.13 In this study, we tested the hypothesis that IL-19
expression would regulate development of intimal hyper-
plasia in a murine common carotid artery ligation model of
vascular restenosis. This study reports that targeted disrup-
tion of the IL-19 gene exacerbates intimal hyperplasia, which
can be reversed by addition of IL-19. Addition of exogenous
IL-19 can reduce intimal hyperplasia, and we suggest several
cellular and molecular mechanisms that may drive these ef-
fects. This suggests that, in addition to immune-modulating
effects, IL-19 can impart a suppressive, anti-inﬂammatory,
type 2 helper T-cell (Th2)elike phenotype to VSMCs.
Materials and Methods
Animals
IL-19 knockout (KO) mice were generated as described.16,17
Homozygous il-19/ mice were identiﬁed by genotyping of
tail DNA by PCR using speciﬁc primers and crossed into the
C57Bl/6 background.17 Wild-type (WT) FVB mice were
purchased from The Jackson Laboratory (Bar Harbor, ME).
Age- and sex-matched male and female littermates were used
for these studies. The partial ligation model of injury was
performed as we described.18 Brieﬂy, mice were anesthetized
by injection of ketamine and xylazine. The left commonThe American Journal of Pathology - ajp.amjpathol.orgcarotid artery was dissected and ligated near the bifurcation.
After 28 days, mice were euthanized and tissue was prepared
for immunohistochemistry (IHC) andmorphological analysis.
Severity of hyperplasia is known to be strain dependent; the
FVB lineage develops a robust, and the C57/B6 develops a
more limited, intimal hyperplasia in response to carotid liga-
tion.19,20 Some mice were injected i.p. with 10 ng/g per day
murine recombinant IL-19 (rIL-19; eBioscience, San Diego,
CA) or an equivalent volume of PBS 5 days per week for the
duration of the study, aswedescribed.21All animal procedures
followed protocols approved by the Temple University Insti-
tutional Animal Care and Use Committee (Philadelphia, PA).
IHC and Quantitative Morphological Characteristics
Digitized images of H&E-stained carotid artery cross sections
were measured and averaged from at least three representative
stained tissue sections (5 mm thick) at least 75 to 100 mm apart
per carotid artery using Image Pro Plus (Media Cybernetics,
Rockville,MD), as we have described.14,18 At least sixmice per
group were used for morphological and IHC analyses. The
circumference of the lumen, the area-encircled internal elastic
lamina (IEL), and the external elastic lamina were quantitated.
The medial area was calculated by subtracting the area deﬁned
by the IEL from the area deﬁned by the external elastic lamina,
and the intimal areawas calculated as the difference between the
area inside the IEL and the luminal area. Tissue ﬁxation, pro-
cessing, IL-19, bromodeoxyuridine (BrdU), SMCa actin, anti-
body, and IHC staining were performed as described.21 CD45
antibody was from Lab Vision, Inc (Fremont, CA). Immuno-
ﬂuorescence was performed as described.21 Brieﬂy, primary
antibody incubationwas followedby30-minute incubationwith
secondary antibody conjugated to Alexa Fluor 568 (red) and
Alexa Fluor 488 (green) (Molecular Probes, Inc., Eugene, OR).
BrdU staining was quantitated as percentage positive of all
cells. VSMC proliferation was counted as the number of BrdU-
positive cells that also stained positive for SMCa actin.
VSMC Culture, Proliferation, Migration, and Adhesion
Assay
Abdominal aortas from WT and IL-19 KO mice were excised,
the endothelial layer was removed, and VSMCs were isolated
as described.18 VSMCs were cultured in Dulbecco’s modiﬁed
Eagle’smediumsupplementedwith 15%fetal calf serum (FCS).
Greater than 95% of isolated cells were SMC actin positive, and
VSMCs from passage 3 to 5 were used. Two different prolif-
eration assays were performed. Brieﬂy, equal numbers of
VSMCs were seeded into 24-well plates at a density of 5000
cells/mL, in the presence or absence of 100 ng/mL murine rIL-
19 (eBioscience). Medium was changed on the fourth day, and
after 1, 4, and 7 days, cells were trypsinized and counted in
triplicate using a standard hemocytometer, as described.14,18
Proliferation was also assayed by ﬂow cytometry using the
CellTrace CFSE Cell Proliferation Kit (Invitrogen, Grand
Island, NY), according to the manufacturer’s directions.222135
Ellison et alCarboxyﬂuorescein diacetate succinimyl ester incorporation
was calculated by the FloJo proliferation platform software
version 2.0. Two different migration assays were performed.15
Brieﬂy, 6.5-mm-diameter transwell Boyden chamber plates
(Costar, Grand Island, NY) with an 8-mm polycarbonate mem-
brane pore sizewere seededwithVSMCs inmedium containing
0.5% FCS. Platelet-derived growth factor (PDGF) at 40 ng/mL
was placed in the lower chamber, and cells were incubated for 2
hours at 37C, at which time cells were ﬁxed and stained.
VSMCs that migrated to the lower surface of the membrane
were quantitated by counting four high-powered ﬁelds (HPFs)
permembrane. For directionalmigration, scratchwoundingwas
performed, as previously described, with wound area quanti-
tated by image analysis.15 Brieﬂy, WT or KO VSMCs were
grown to 80% conﬂuence in a four-chamber slide in growth
medium. A 2-mm uniform scratch was made using a cell
scraper, which was cut to 2mm. For some samples, themedium
was replaced with medium plus IL-19. The chamber slide was
then returned back to a cell culture incubator for 0 to 24 hours.
The slide was then ﬁxed with paraformaldehyde and stained
with H&E. Images were captured at 4 magniﬁcation. Exper-
iments were performed in triplicate from VSMCs isolated from
threedifferentKOandWTmice.For adhesion,WTor IL-19KO
VSMCswere cultured on glass slides and stimulatedwith tumor
necrosis factor (TNF)a for 16hours; then, lBCECF/AM-labeled
THP1 monocytes were incubated with the monolayers, and
adherent cells were quantitated by microscopy, as we
described.23 In some experiments, 10 mg/mL anti-intercellular
adhesion molecule (ICAM) 1, vascular cell adhesion molecule
(VCAM) 1, or IgG1 antibody was added to VSMCmonolayers
1 hour before the addition of THP1 cells, as described.24
RNA Extraction and Quantitative RT-PCR
For quantiﬁcation of gene expression, VSMCs were serum
starved in 0.5% FCS for 48 hours, then stimulated with 10 ng/
mL TNFa for the indicated times. RNA from cultured VSMCs
was isolated and reverse transcribed into cDNA, as we have
described, and target genes were ampliﬁed using an Eppendorf
Realplex4 Mastercycler (New York, NY).13 Multiple mRNAs
(CT values) were quantitated simultaneously by the Eppendorf
software version 4.0. Primer pairs were purchased from Inte-
grated DNA Technologies (Coralville, IA), and SYBR Green
was used for detection. The following primer pairs were used:
mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
50-GCAAGGACACTGAGCAAGAG-30 (forward) and 50-
GGGTCTGGGATGGAAATTGT-30 (reverse); mouse mono-
cyte chemoattractant protein (MCP) 1, 50-TTAAAAACCTG-
GATCGGAACCAA-30 (forward) and 50-GCATTAGCTTC-
AGATTTACGGGT-30 (reverse); mouse IL-1b, 50-CTAAT-
AGGCTCATCTGGGATCC-30 (forward) and 50-GGTCCG-
TCAACTTCAAAGAAC-30 (reverse); and mouse TNFa, 50-
CTTCTGTCTACTGAACTTCGGG-30 (forward) and 50-
CAGGCTTGTCACTCGAATTTTG-30 (reverse). For VSMC
phenotype analysis, equal numbers ofWT or IL-19/VSMCs
were serum starved in 0.5% FCS for 48 hours, then stimulated2136with 15%FCS for 6 or 24 hours. RNAwas reverse transcribed,
and target genes were ampliﬁed and quantitated by Applied
Biosystems 7500 software (Foster City, CA), as described.25
Probe sets for murine SM22a (reference Mm00441660-m1),
murine SMCa-actin (reference Mm01546133-m1), calpo-
nin (reference Mm00487032-m1) were purchased from
Applied Biosystems.
Western Blot Analysis
Protein extracts from cultured VSMCs were made as
described,13,14,18 separated by SDS-PAGE, transferred to a
nitrocellulose membrane, and incubated with a 1:4000 dilution
of primary antibody [IL-19, heme oxygenase-1 (HO-1),
ICAM1, VCAM1, TNFa, MCP-1, and IL-1b; Santa Cruz, Inc.,
Dallas, TX] and a 1:6000 dilution of secondary antibody. Equal
loading of protein extracts on gels was veriﬁed by Ponceau S
staining of the membrane, and blotting with the housekeeping
protein anti-GAPDH (1:7000 dilution; Biogenesis, Inc., Poole,
UK), and reactive proteins were visualized using enhanced
chemiluminescence. The intensity of each bandwas quantitated
using ImageJ software version 1.48 (NIH, Bethesda, MD).
Statistical Analysis
Results are expressed as means  SEM. Differences be-
tween groups were evaluated with the use of analysis of
variance to evaluate differences between individual mean
values or by t tests, where appropriate. Differences were
considered signiﬁcant at P < 0.05.
Results
Lack of IL-19 Exacerbates Intimal Hyperplasia
To deﬁne a fundamental role for IL-19 in neointimal hyper-
plasia, we used IL-19 KO mice. The left common carotid ar-
tery of age- and sex-matched IL-19/ and WT littermates in
the C57Bl/6 background was subject to carotid artery ligation
near the carotid bifurcation. After 28 days, arteries were
recovered and divided into sections, and vascular compart-
ments were quantitated. The neointima/intima (N/I) ratio was
signiﬁcantly less in WT mice (0.50  0.12) compared with
IL-19 KO mice (0.83  0.09) (nZ 9 for WT and 13 for IL-
19/; P < 0.05) (Figure 1A). Similarly, the percentage ste-
nosis was also signiﬁcantly less in WT (49.04%  8.1%)
compared with IL-19KO (74.59% 4.55%) mice (P< 0.01).
The robust response to ligation injury in the IL-19 KO mice is
noteworthy considering the C57B/6 strain is particularly un-
responsive to this type of injury.18,19 This suggests that lack of
IL-19 by targeted disruption exacerbates intimal hyperplasia.
Injection of Recombinant IL-19 into IL-19/ Mice
Reduces/Rescues Intimal Hyperplasia
To further conﬁrm the role of IL-19 in regulation of neo-
intimal hyperplasia, IL-19 KO mice were subject to carotidajp.amjpathol.org - The American Journal of Pathology
Figure 1 IL-19 regulates neointimal hyperplasia. A: IL-19/ mice demonstrate exacerbated response to ligation injury compared with WT age- and sex-
matched littermates. Quantitative morphological analysis determines a signiﬁcantly increased N/I ratio in IL-19/ (nZ 13) compared with WT (nZ 9) mice.
B: Injection of recombinant IL-19 into IL-19/ mice can rescue the IL-19/ response to injury phenotype. Quantitative morphological analysis determined
signiﬁcantly decreased N/I ratio in mice injected with 10 ng/g per day rIL-19 i.p. (n Z 11) or PBS (n Z 10) 5 days per week for 28 days. C: IL-19 reduces
intimal hyperplasia in FVB WT mice. Injection of recombinant IL-19 signiﬁcantly decreased the N/I ratio in mice injected with 10 ng/g per day rIL-19 i.p. (nZ
11) or PBS (n Z 10) 5 days per week for 28 days (P < 0.01). Representative photomicrographs are stained with H&E. *P < 0.05, **P < 0.01, and
***P < 0.001. Original magniﬁcation, 200.
IL-19 Reduces Neointimal Hyperplasiaartery ligation. Some mice were injected i.p. with 10 ng/g
per day rIL-19 5 days per week, others with an equivalent
volume of PBS as controls, and vascular compartments were
quantitated after 28 days. IL-19 KO mice injected with
IL-19 had a signiﬁcantly lower N/I ratio (0.40  0.11)
compared with PBS control mice (1.20  0.37) (nZ 11 for
rIL-19 and 10 for PBS; P < 0.05) (Figure 1B). Likewise,
percentage stenosis was signiﬁcantly less in IL-19einjected
mice (38.36%  5.86%) compared with PBS control mice
(60.60%  5.96%) (P Z 0.01). Because addition of IL-19
to IL-19/ mice can reduce or rescue intimal hyperplasia,
these data reinforce the hypothesis that IL-19 can regulate
carotid artery ligationeinduced carotid artery intimal
hyperplasia.
Injection of Recombinant IL-19 Reduces Intimal
Hyperplasia in WT Mice
We hypothesized that IL-19 would decrease intimal hyper-
plasia subsequent to carotid artery ligation. FVB WT mice
were used for these studies because it has been shown that this
particular strain has a robust response to this type of arterialThe American Journal of Pathology - ajp.amjpathol.orginjury.19,20 One cohort of mice was injected i.p. with 10 ng/g
per day of rIL-19 5 days per week, and the other with an
equivalent volume of PBS as controls. Quantitative morpho-
logical analysis determined a signiﬁcant decrease in N/I ratio
in IL-19einjected mice (0.87  0.20) compared with PBS
controls (2.14  0.33) (n Z 10 for rIL-19 and 9 for PBS;
P < 0.01) (Figure 1C). The percentage stenosis was signiﬁ-
cantly decreased in IL-19einjected mice (62.00%  4.9%)
compared with PBS controls (85.01%  3.6%) (PZ 0.001).
IL-19 Polarization of Adaptive Immunity
IL-19 is a putative Th2 IL, and considering immune cells
participate in vascular injury, we hypothesized that polariza-
tion of adaptive immunity to the Th2 phenotype might account
for decreased intimal hyperplasia observed in IL-19etreated
mice.26 The global immunological status of these mice was
determined by quantitation of type 1 helper T-cell (Th1) and
Th2 lymphocyte marker expression in splenocytes removed
immediately from mice at the termination of the study.
Quantitative RT-PCR of the Th1marker gene T-bet expression
inWTC57BL/6micewas not signiﬁcantly different compared2137
Ellison et alwith IL-19/ mice (0.91  0.06 versus 1.04  0.04)
(Figure 2A). Similarly, mRNA levels of the Th2 marker
GATA3 were not signiﬁcantly different between the two
groups of mice (0.95  04 versus 1.04  0.03) (Figure 2B).
This suggests that IL-19 KO mice are not polarized toward a
proinﬂammatory, Th1-biased immune response, suggesting
that this is not a major mechanism for reduced intimal hy-
perplasia in IL-19etreated mice.
IL-19 Decreases Inﬂammatory Cell Inﬁltrate in
Neointima
To characterize inﬂammatory cell inﬁltrate in neointima
from these mice, serial sections were immunostained with
the pan-leukocyte marker CD45. Signiﬁcantly more CD45-
positive cells were observed in IL-19 KO mice compared
with WT mice (7.75  2.06 versus 2.25  1.5 cells per
HPF; PZ 0.05) (Figure 2C). These differences in leukocyte
inﬁltrate in ligated arteries were unexpected, considering
that there were no global differences in adaptive immunity
in WT versus IL-19/. To determine whether IL-19 could
affect leukocyte adhesiveness, we treated the human
monocyte line THP-1 with IL-19, and quantitated expres-
sion of leukocyte adhesion molecules. IL-19 treatment had
no effect on abundance of mRNA for LFA-1a, MAC1aM,
or VLA4, all counterreceptors for endothelial adhesion
molecules (Figure 2D). Together, these data suggested
increased localized inﬂammation at the site of injury in these
mice, and perhaps direct anti-inﬂammatory effects of IL-19
on VSMCs. In subsequent experiments, we turned our
attention to direct effects of IL-19 on VSMCs.Figure 2 IL-19/ mice are not Th1 polarized. Spleen removed from
age-matched WT and IL-19/ littermates 28 days after carotid ligation;
mRNA was extracted and reverse transcribed, and ampliﬁed using the
primer pairs listed in Materials and Methods. No signiﬁcant difference was
noted in mRNA abundance for T-bet (A) or GATA3 (B) (n Z 8 spleens in
each group). C: Lack of IL-19 results in increased leukocyte inﬁltrate in
ligated arteries. Serial sections were immunostained using anti-CD45
antibody. Positive cells were counted from at least four stained tissue
sections from four different mice, and values expressed are positive cells
per HPF. D: IL-19 does not increase CAM expression in monocytes. THP1
cells were treated with rIL-19, and CAM mRNA expression was quantitated
by quantitative RT-PCR. There is no signiﬁcant difference in mRNA
expression between IL-19 and untreated THP1 cells. *P < 0.05.
2138IL-19 Is Expressed in Stimulated Murine VSMCs
VSMCs in the restenotic lesion synthesize and respond to
numerous cytokines, which initiates and maintains VSMC
proliferation and migration. WT VSMCs were challenged
with various stimuli, and expression of IL-19 in these cells
was assessed by using Western blot analysis. Although most
stimuli increase IL-19 expression higher than basal levels,
signiﬁcant increases were only noted with TNFa and T-cell
conditioned medium, which is a mix of several inﬂamma-
tory cytokines (Figure 3A). This suggests IL-19 expression
is responsive to inﬂammatory cytokines and may participate
in intimal hyperplasia subsequent to vascular injury.
IL-19/ VSMCs Proliferate More Rapidly than WT
VSMCs
VSMCs are the major effector cell involved in the develop-
ment of intimal hyperplasia. Three different, but comple-
mentary, approaches were used to determine IL-19 effects on
VSMC proliferation. First, VSMC cultures were established
from explants from aortas from age-matchedWT or IL-19/
mice, and equal numbers were seeded into 24-well plates and
grown in Dulbecco’s modiﬁed Eagle’s medium. Some were
treated with IL-19. At 4 and 7 days, cells were recovered and
counted. VSMCs isolated from IL-19 KO mice proliferate
more rapidly than do WT VSMCs at both 4 and 7 days after
seeding (24.2  3.1  104 versus 34.2  1.7  104 cells per
mL for WT versus IL-19/; P < 0.01, for 7 days)
(Figure 3B), which could be signiﬁcantly inhibited by the
addition of recombinant IL-19 to cultures (34.2  1.7  104
versus 25.07  2.0  104 cells per mL for IL-19/ and IL-
19/ VSMCs plus 100 ng/mL rIL-19; P < 0.05). Addition
of recombinant IL-19 could also reduce proliferation of WT
VSMCs (24.2 3.1 104 versus 19.07 1.6 104 cells per
mL), but not signiﬁcantly (P Z 0.20). In a second assay,
VSMCs were ﬂuorescently labeled with CFSE, then stimu-
lated with 10% FCS for 72 hours. Fluorescent label incor-
poration was quantitated by ﬂow cytometry. IL-19/
VSMCs proliferate signiﬁcantly more rapidly than do WT
VSMCs [3461  228 versus 2528  110 (P < 0.05), for IL-
19/ and WT VSMCs, respectively]. More important,
addition of rIL-19 to WT cells also signiﬁcantly decreases
their proliferation (P < 0.05).
To determine whether IL-19 regulated proliferation in vivo,
in a third experiment, WT and IL-19/ mice were injected
with the nucleotide analogue BrdU. Fourteen days after liga-
tion injury, carotid arteries were recovered and immuno-
stained, and positive cells were quantitated. IL-19/mice had
a signiﬁcantly increased number of proliferating cells in the
neointima compared with WT mice (20.55%  12% versus
55.78% 4.2%, forWT and IL-19/, respectively;P< 0.01)
(Figure 3D). To determine the number of BrdU-positive cells
that were VSMCs, sections were costained with anti-BrdU and
SMCa actin antibody. Although IL-19/ mice had a signif-
icantly increased number of proliferating cells, there were alsoajp.amjpathol.org - The American Journal of Pathology
Figure 3 A: IL-19 is expressed in murine
VSMCs. Representative immunoblot of mouse
VSMCs explanted from abdominal aortas, which
were serum starved, then stimulated with the
factors shown. Expression was quantitated by
densitometry and normalized to GAPDH expression
from three identical experiments. B: IL-19 regu-
lates VSMC proliferation. Equal numbers of age-
matched WT or IL-19/ VSMCs were counted at
the indicated days after seeding. rIL-19 (100 ng/
mL) was added to some samples. Addition of rIL-
19 signiﬁcantly reduced proliferation of IL-19/
VSMCs. C: Proliferation assayed by ﬂuorescent
label ﬂow cytometry using the CellTrace CFSE Cell
Proliferation Kit, with CFSE incorporation calcu-
lated by the proliferation platform of the FloJo
software program. D: IL-19 increases proliferation
in vivo. BrdU was injected into ligated WT or IL-19/
mice. Mice were sacriﬁced 14 days after ligation, and
BrdU incorporation was detected by anti-BrdU anti-
body. Positive cells were counted from at least four
stained tissue sections from four different mice, and
values expressed are positive cells per HPF. E: IL-19
regulates VSMC proliferation in vivo. Representative
photomicrograph of BrdU/SMCa actin dual IHC.
Arrows indicate examples of dual staining. Values are
expressed as number of BrdU-positive cells that also
stained positive for SMCa actin per HPF. *P < 0.05,
**P < 0.01. TCM, T-celleconditioned media.
IL-19 Reduces Neointimal Hyperplasiasigniﬁcantly more proliferating cells that were SMCa actin
positive in IL-19/ compared with WT mice (5.55  2.6
versus 15.78  4.2, per HPF, for WT and IL-19/, respec-
tively; P < 0.05) (Figure 3E).
VSMCs are plastic and can assume a synthetic phenotype
in response to injury and stimulation. WT and IL-19/
VSMCs were serum starved, then stimulated with FCS.
Expression of several SMC phenotype markers was deter-
mined by quantitative RT-PCR. IL-19/ VSMCs do not
express signiﬁcantly different amounts of SMC phenotype
markers compared with WT VSMCs (Figure 4A). Never-
theless, both in vivo and ex vivo experiments point to direct
anti-proliferative effects of IL-19 on proliferation of VSMC.IL-19/ VSMCs Migrate More Rapidly than WT VSMCs
Medial to intimal migration of VSMCs is an important cellular
event in the development of neointimal hyperplasia. To
determine differences in migration between WT and IL-19/
VSMCs, cultures were established from explants from aortas
from age-matchedWTor IL-19/mice. VSMCswere seededThe American Journal of Pathology - ajp.amjpathol.orginto Boyden chambers, and differences in chemokinesis were
quantitated by counting cells that migrated in response to
PDGF. A signiﬁcant difference in migration between IL-19/
VSMCs and WT VSMCs (49.2  5.1 versus 33.3  1.3
VSMCs per HPF; P < 0.001) was observed (Figure 4B).
Interestingly, IL-19/ VSMCs migrate more rapidly than
WT, even in the absence of chemotactic stimuli (39.2  3.2
versus 8.6  0.95 VSMCs per HPF; P < 0.001). In a second
assay, scratch wounding of VSMC monolayers was per-
formed. VSMCs from IL-19/ mice migrate into the wound
area signiﬁcantly more rapidly than doWTVSMCs (568 69
versus 243 49 for wound area of WT and KO, respectively;
P < 0.05) (Figure 4C). Together, this indicates that IL-19
expression plays a role in regulation of VSMC migration.Lack of IL-19 Increases Inﬂammatory Gene Expression
in VSMCs
Increased inﬂammatory cell inﬁltrate without immune
system polarization suggested direct anti-inﬂammatory
effects of IL-19 on VSMCs. We tested if VSMCs from2139
Figure 4 IL-19 regulates VSMC migration, but not VSMC phenotype. A:
IL-19 does not modify VSMC phenotype. WT or IL-19/ VSMCs were serum
starved, then stimulated with FCS. SMC phenotype marker expression,
quantitated by quantitative RT-PCR, indicates no signiﬁcant difference
between WT and IL-19/ VSMCs for any marker. B: WT or IL-19/ VSMCs
were seeded onto the top chamber of a modiﬁed Boyden chamber in me-
dium containing 0.2% bovine serum albumin, with or without 40 ng/mL
PDGF as a chemoattractant in the lower chamber. Values are means from
three experiments performed in triplicate from three independent groups of
VSMCs. IL-19 reduces VSMC wound healing. C: Scratch wound migration of
IL-19/ VSMCs. Cells were stained with hematoxylin. Dashed lines deﬁne
original scratched area. Photomicrograph is representative of three inde-
pendent experiments. Quantitative analysis of scratch wound area is from
three different groups of treated VSMCs. *P < 0.05, ***P < 0.001 versus
control. Original magniﬁcation, 40.
Ellison et alIL-19 KO mice responded to inﬂammatory stimuli more
robustly than WT VSMCs. Aortic VSMCs were isolated
from age- and sex-matched littermates, cultured, and then
challenged with the proinﬂammatory cytokine, TNFa. In-
ﬂammatory cytokine mRNA expression was determined by
quantitative RT-PCR. Expression levels of TNFa, IL-1b,Figure 5 Increased inﬂammatory gene expression in IL-19/ VSMCs. VSMCs fr
with 10 ng/mL TNFa for the times indicated, at which time total RNA was reverse tran
TNFa (B), and IL-1b (C) mRNA was normalized to GAPDH. Differences in WT versus IL
and densitometric quantiﬁcation of cytokine protein expression in WT and IL-19 V
otherwise noted; yP < 0.05, quantitated from three different Western blot analyse
2140and MCP-1, all potent proinﬂammatory and chemotactic
cytokines, were signiﬁcantly increased in VSMCs
explanted from IL-19 KO mice compared with VSMCs
from WT mice (Figure 5, AeC). Similarly, each cytokine
protein tested from IL-19 KO mice was signiﬁcantly
increased at 30 hours after TNFa stimulation compared
with WT VSMCs (Figure 5D). Together, these data sug-
gest an enhanced response of IL-19/ VSMCs to in-
ﬂammatory stimuli.
IL-19 Decreases CAM Expression in VSMCs
Leukocyte entrapment in neointimal VSMCs contributes to
development of restenosis.27 We previously determined
that IL-19 decreases CAM expression in human endothe-
lial cells (ECs).23 To determine whether IL-19 affected
leukocyte adhesion to VSMCs, several experiments were
performed. First, VSMCs isolated from WT and IL-19/
aortas were challenged with TNFa, and ICAM1 and
VCAM1 expression levels were determined by using
Western blot analysis. A signiﬁcant increase in both CAMs
in IL-19/ VSMCs compared with WT VSMCs was
observed (Figure 6A). The second experiment used a
VSMC monolayer adhesion assay. WT or IL-19 KO
VSMCs were cultured on glass slides and stimulated with
TNFa for 16 hours, then labeled THP1 monocytes were
incubated with the monolayers, and adherent cells were
quantitated by microscopy. Signiﬁcantly more monocytes
adhered to IL-19/ VSMCs compared with WT VSMCs
(89.1  15.3 versus 47.3  14.1 adherent cells per HPF for
KO and WT, respectively; P < 0.05) (Figure 6B). In a third
experiment, anti-ICAM1 or VCAM1 antibody was added to
the adhesion assay using IL-19/ VSMCs. Anti-ICAM1
antibody signiﬁcantly inhibits THP1-VSMC adherence
(99.1  10.1 versus 57.9  14.3 adherent cells per HPF forom WT and IL-19/ mice were serum starved for 48 hours, then stimulated
scribed and target mRNA was quantitated by quantitative RT-PCR. MCP-1 (A),
-19/ VSMCs are signiﬁcant, where indicated. D: Representative immunoblot
SMCs. *P < 0.05, **P < 0.01 (nZ 3; B), for all targets at that time, unless
s of IL-19/ versus WT control VSMCs (D).
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Figure 6 IL-19 reduces ICAM-1 and VCAM-1 expression, and IL-19 reduces leukocyteesmooth muscle cell interaction. A: ICAM-1 and VCAM-1 expression is
signiﬁcantly increased in IL-19/ VSMCs. WT or IL-19/ VSMCs were serum starved, then stimulated with TNFa for the times indicated. Extracts were blotted
with the indicated antibodies, and protein expression was quantitated by densitometry and normalized to GAPDH expression from three experiments. A
representative of three Western blot analyses is shown. B: Monocyte adhesion is signiﬁcantly increased in IL-19/ VSMCs. VSMCs were grown on glass cover
slides and stimulated with TNFa for 16 hours; labeled THP1 monocytes were incubated with the monolayers, and adherent cells were quantitated by counting
per HPF. C: Enhanced leukocyte-VSMC adhesion in IL-19/ VSMCs is reduced by anti-CAM antibody. Anti-ICAM1, VCAM1, or IgG1 antibody (10 mg/mL) was
added to VSMC monolayers 1 hour before addition of THP1 cells. D: IL-19 signiﬁcantly reduces ICAM-1 and VCAM-1 protein abundance in primary human VSMCs.
VSMCs were pretreated with IL-19, then stimulated with TNF-a for 24 hours. Western blot analysis was quantitated by densitometry from at least three
experiments, *P < 0.05 for times indicated, and is representative of at least three experiments. Original magniﬁcation, 200 (B).
IL-19 Reduces Neointimal Hyperplasiacontrol and ICAM1 antibody, respectively; P < 0.05)
(Figure 6C). Anti-VCAM1 antibody decreased adhesion,
but not signiﬁcantly (P Z 0.068). In a fourth experiment,
primary human VSMCs were treated with 100 ng/mL re-
combinant IL-19. IL-19 treatment signiﬁcantly decreased
CAMs abundance in human VSMCs (Figure 6D). Together,
these data indicate that IL-19/ VSMCs are more adhesive
thanWT, and suggest that IL-19 plays a role in regulation of
adhesion molecule expression and leukocyte adhesion.
Discussion
To our knowledge, this is the ﬁrst study to use IL-19/
mice to investigate a role for IL-19 in the development of
intimal hyperplasia indicative of vascular restenosis. The
major ﬁnding is the identiﬁcation of IL-19 as an integral
regulator of the VSMC response to carotid artery ligation
injury. Lack of IL-19 leads to increased intimal hyperpla-
sia, which is noteworthy considering that, compared withThe American Journal of Pathology - ajp.amjpathol.orgother strains, C57Bl/6 mice generally demonstrate a more
limited response to ligation injury relative to other
strains.19,20 More important, IL-19 KO mice injected with
rIL-19 demonstrated signiﬁcantly less intimal hyperplasia
compared with control mice injected with PBS. This rescue
effect established the speciﬁcity of effect of IL-19 in the
development of intimal hyperplasia. Addition of recombi-
nant IL-19 to WT FVB-strain mice signiﬁcantly reduces
intimal hyperplasia. The observation that addition of IL-19
was effective in reducing intimal hyperplasia is particularly
striking considering that relative to other strains, FVB mice
respond to ligation injury in a robust manner.19,20 IL-19
expression can be induced by inﬂammatory factors in
cultured VSMCs. Because lack of IL-19 is deleterious, and
exogenous addition of IL-19 is protective, these in vivo
experiments support the hypothesis that IL-19 expression
in injured arteries may be a compensatory, counter-
regulatory mechanism to reduce the vascular response to
injury.2141
Ellison et alLittle pertinent literature exists on other Th2 ILs in the
development of restenosis, and data are somewhat con-
tradictory. Although considered to be anti-atherosclerotic,
studies focusing on a role for IL-10 in the development of
intimal hyperplasia subsequent to arterial injury are
inconclusive. For example, IL-10/ mice subject to ca-
rotid artery ligation demonstrated no signiﬁcant differ-
ences in neointimal hyperplasia compared with WT
controls.28 In further contrast to our study, WT mice
injected daily with 1 mg rIL-10, which is much more than
the 10 ng/g per day IL-19 used in this study, also
demonstrated neointimal hyperplasia to the same degree
as PBS controls. This same group reported that mice
injected with adenoviral IL-10 developed intimal hyper-
plasia to the same degree as control mice receiving empty
adenovirus. On the other hand, hypercholesterolemic
rabbits treated with 50 mg rIL-10 showed signiﬁcantly less
neointimal hyperplasia and inﬂammatory cell inﬁltrate
after balloon angioplasty.29 The differences noted be-
tween IL-19 and IL-10 efﬁcacy in response to vascular
injury may reﬂect differences in the etiology of athero-
sclerosis and ligation-induced neointimal hyperplasia.
In humans, a signiﬁcant decrease in Th2-dependent IL
concentrations was observed after percutaneous coronary
angioplasty, suggesting an acute Th1-biased environment
immediately after the procedure, consistent with the
response to injury hypothesis.30 In a previous study, we
reported that similar i.p. injection of rIL-19 into LDLR/
mice for 12 weeks could polarize the immune response to
the Th2 phenotype.21 Similarly, another study reported
increased proinﬂammatory responses in IL-19/ mice, but
in our hands, the IL-19/ mouse did not demonstrate sta-
tistically signiﬁcant Th1 polarization. This could reﬂect
differences in the type of injury or inﬂammatory insult, or
that 28 days’ injection is not sufﬁcient time for IL-19 to
polarize T-cell phenotype. Because IL-19 polarization of
adaptive immunity appeared not to be a major mechanism of
protection, along with the observation that IL-19 did not
decrease expression of leukocyte adhesion molecules, we
focused our attention to direct effects of IL-19 on VSMCs.
As part of the vascular response to injury, activated
VSMCs proliferate and synthesize cytokines to which they
respond to in an autocrine manner, sustaining the progression
of intimal hyperplasia.6,7 The addition of recombinant IL-19
to cultured human VSMCs is anti-proliferative for human
VSMCs, and this study extends that ﬁnding both in cultured
VSMCs and in vivo.13 Consistent with a counterregulatory
response mechanism, lack of IL-19 results in an increased
rate of VSMC proliferation. More important, similar to the
in vivo rescue experiment, increased proliferation of IL-19/
VSMCs can be signiﬁcantly reduced by the addition of IL-19
to culture media. Two studies have reported anti-proliferative
effects of IL-10 on VSMCs, where it was proposed that the
observed growth-inhibitory effects were due to inhibition of
NF-kB. In previous studies, we did not observe any inhibi-
tion of NF-kB activation in cultured VSMCs, an important2142distinction that contrasts the anti-proliferative mechanism of
IL-19 from IL-10.13,14
Migration of normally quiescent VSMCs from the media
into the lumen of the vessel is a major cellular event in the
etiology of vascular restenosis. We have previously reported
that addition of recombinant IL-19 to cultured human
VSMCs reduces their migration.15 This study using IL-19/
VSMCs in both Boyden chambers and the scratch wound
assay extends that ﬁnding and is particularly interesting in
that it demonstrates that VSMCs lacking IL-19 can migrate
more rapidly, even in the absence of PDGF, suggesting that
IL-19 is an important mediator of VSMC motility.
Similar to many vascular interventional procedures in
humans, ligation of the murine carotid artery elicits expres-
sion of growth factors and inﬂammatory cytokines from
resident vascular cells and inﬁltrating inﬂammatory cells.
This response to injury initiates and maintains VSMC pro-
liferation and migration. We were surprised to ﬁnd that there
were signiﬁcantly more inﬂammatory cells in ligated carotid
arteries in IL-19/mice compared withWTmice, especially
considering that IL-19 did not polarize adaptive immunity in
these animals. Together with the potent suppressive effects of
IL-19 on VSMCs, this suggested that local inﬂammation
would be regulated by VSMCs themselves, which prompted
us to determine whether lack of IL-19 resulted in an enhanced
response of VSMCs to inﬂammatory stimuli. Consistent with
a compensatory anti-inﬂammatory mechanism, IL-19/
VSMCs expressed more IL-1b, TNFa, and MCP-1 mRNA.
Expression of inﬂammatory genes by activated VSMCs
could contribute to intimal hyperplasia in multiple ways.
First, these cytokines are all mitogenic for VSMCs, and their
expression could drive autocrine proliferation of VSMCs in
the restenotic lesion. Second, chemokine expression by
vascular cells participates in leukocyte recruitment to the
atherosclerotic lesion. Enhanced expression of these cyto-
kines may account for the greater leukocyte burden in carotid
artery from IL-19/ mice. Third, these chemokines could
also contribute to autocrine migration of VSMCs into the
developing neointima. In both ECs and VSMCs, adhesion
molecule expression is driven by chemokine expression.
Leukocyte entrapment in neointimal VSMCs contributes to
development of restenosis; thus, a fourth mechanism is
demonstrated by the ﬁnding that IL-19/ VSMCs express
more ICAM1 and VCAM1 compared with WT VSMCs.
Addition of IL-19 can reduce expression of both ICAM1 and
VCAM1 in human ECs.23 The importance of these adhesion
molecules is illustrated by the ﬁnding that addition of anti-
CAM antibody can reduce the enhanced adhesive proper-
ties of IL-19/. Although this does not imply that these are
the only two CAMs that may play a role in adhesion, it does
demonstrate that they are important in mediation of the
enhanced adhesiveness displayed by IL-19/ VSMCs.
Consequently, increased cytokine expression in VSMCs
could result in increased expression of adhesion molecules,
which could explain the observed increases in leukocyte
inﬁltrate in ligated arteries from IL-19 mice. The HO-1 is aajp.amjpathol.org - The American Journal of Pathology
IL-19 Reduces Neointimal Hyperplasiacytoprotective protein shown to have anti-restenotic effects,
and we have previously reported that IL-19 could induce HO-
1 expression in primary human VSMCs.31 In this study,
however, we observed no difference in HO-1 expression
between WT and IL-19 VSMCs (data not shown).
In summary, IL-19 can reduce the vascular response to
injury, primarily by attenuating VSMC migration, prolif-
eration, and inﬂammatory gene expression. Expression of
IL-19 by activated VSMCs may represent a compensatory,
autoregulatory, autocrine, or paracrine counterregulatory
feedback mechanism to promote resolution of the vascular
response to injury by direct suppression of VSMC
activation.References
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